collaborations

Addex has established three deals that demonstrate not only the value of its drug discovery capabilities but also that its drug development capabilities can meet the highest standards in the industry.

In December 2004, Addex Pharmaceuticals entered into a collaboration and licence agreement with Ortho-McNeil, a Johnson & Johnson company. to discover and develop positive allosteric modulators (PAM) of metabotropic glutamate receptor 2 (mGluR2). The mGluR2 PAM approach is a clinically validated strategy in both anxiety and schizophrenia.

In December 2007, Addex entered into an exclusive license and collaboration agreement with Merck & Co., Inc. affiliate Merck Sharp & Dohme to discover and develop mGluR4 PAM. The partnership includes a number of mGluR4 PAM discovered at Addex. Merck is responsible for preclincal and clinical development.

In January 2008, Addex entered an exclusive worldwide license agreement with Merck & Co., Inc. to develop ADX63365, an orally available drug candidate for the potential treatment of schizophrenia and other undisclosed indications.

Addex is seeking additional partners for several other products in its pipeline and discovery pipeline. Please contact us directly to discuss these opportunities.